Abstract
The endogenous cannabinoid, anandamide, has been shown to attenuate naloxone-precipitated opiate withdrawal in rodents. Here we show that the spontaneous, but not the naloxone-precipitated withdrawal syndrome in morphine-dependent mice is attenuated by the inhibitor of carrier-mediated anandamide transport N-(4-hydroxyphenyl) arachidonylethanolamide (AM404) (2 and 10 mg/kg, i.p.). These results suggest that spontaneous but not opioid antagonist-precipitated withdrawal is associated with dynamic changes in endogenous cannabinoid signaling.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Arachidonic Acids / metabolism*
-
Arachidonic Acids / pharmacology*
-
Biological Transport / drug effects
-
Depression, Chemical
-
Dose-Response Relationship, Drug
-
Endocannabinoids
-
Mice
-
Morphine Dependence / metabolism*
-
Naloxone / pharmacology
-
Narcotic Antagonists / pharmacology
-
Polyunsaturated Alkamides
-
Substance Withdrawal Syndrome / drug therapy*
-
Substance Withdrawal Syndrome / metabolism
Substances
-
Arachidonic Acids
-
Endocannabinoids
-
Narcotic Antagonists
-
Polyunsaturated Alkamides
-
Naloxone
-
anandamide
-
N-(4-hydroxyphenyl)arachidonylamide